These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 32048247)
1. Inhibition of monoglyceride lipase by proton pump inhibitors: investigation using docking and in vitro experiments. Dahabiyeh LA; Abu-Rish EY; Taha MO Pharmacol Rep; 2020 Apr; 72(2):435-442. PubMed ID: 32048247 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole. Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807 [TBL] [Abstract][Full Text] [Related]
3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Li XQ; Andersson TB; Ahlström M; Weidolf L Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107 [TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors versus Brilhante RS; da Rocha MG; de Oliveira JS; España JD; Pereira VS; Scm Castelo-Branco D; A Pereira-Neto W; Sidrim JJ; A Cordeiro R; Rocha MF Future Microbiol; 2019 Apr; 14():489-497. PubMed ID: 31033338 [No Abstract] [Full Text] [Related]
5. Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study. Pasupuleti B; Gone V; Baddam R; Venisetty RK; Prasad OP Curr Drug Metab; 2020; 21(2):126-131. PubMed ID: 32067615 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887 [TBL] [Abstract][Full Text] [Related]
7. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Huang Q; Liu Q; Yin T; Hu L; Ding H; Liu S; Jiang Y Eur J Clin Pharmacol; 2020 Jun; 76(6):833-842. PubMed ID: 32157329 [TBL] [Abstract][Full Text] [Related]
8. Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro. Escoffier J; Arnaud B; Kaba M; Hograindleur JP; Le Blévec E; Martinez G; Stévant I; Ray PF; Arnoult C; Nef S Andrology; 2020 Nov; 8(6):1795-1804. PubMed ID: 32609951 [TBL] [Abstract][Full Text] [Related]
9. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Akter S; Hassan MR; Shahriar M; Akter N; Abbas MG; Bhuiyan MA Alzheimers Res Ther; 2015 Dec; 7():79. PubMed ID: 26714488 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. Welage LS; Berardi RR J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250 [TBL] [Abstract][Full Text] [Related]
11. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Caro JJ; Salas M; Ward A Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776 [TBL] [Abstract][Full Text] [Related]
12. Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women. Terranova C; Petrella C; Improta G; Severini C; Signore F; Damiani P; Plotti F; Scarpignato C; Angioli R Eur J Pharm Sci; 2014 Feb; 52():125-31. PubMed ID: 24215738 [TBL] [Abstract][Full Text] [Related]
13. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560 [TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction. Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859 [TBL] [Abstract][Full Text] [Related]
16. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802 [TBL] [Abstract][Full Text] [Related]
18. Enantioselective Binding of Proton Pump Inhibitors to Alpha1-Acid Glycoprotein and Human Serum Albumin-A Chromatographic, Spectroscopic, and In Silico Study. Dombi G; Tyukodi L; Dobó M; Molnár G; Rozmer Z; Szabó ZI; Fiser B; Tóth G Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39408903 [TBL] [Abstract][Full Text] [Related]